Clinical Trials Logo
  1. Home
  2. Clinical High Risk for Psychosis
  3. NCT03829527

Evaluation of the Treatment Approach ROBIN — Robin  

Clinical High Risk for Psychosis Clinical Trial

Official title:
Evaluation of the Treatment Approach ROBIN (Standardized Manual and Smartphone App) for Adolescents With High Risk for Developing a Psychotic Disorder

Clinical Trial Summary

The prevention of schizophrenia and other psychotic disorders has led researchers to focus on early identification of individuals at Clinical High Risk (CHR) for psychosis and to treat the at-risk symptoms in the pre-psychotic period. Although at-risk symptoms such as attenuated hallucinations or delusions are common in adolescents and associated with a marked reduction in global functioning, the evidence base of effective interventions for adolescents at CHR state and even first-episode psychosis is limited. To fill this gap, the clinicians from the early intervention center in Zurich have developed the treatment approach "Robin" (standardized manual and smartphone App) for adolescents with high risk for developing a psychotic disorder. The treatment approach is based on existing therapy strategies for adolescents with first episode of psychosis and the available recommendations for adults with at-risk symptoms. The evaluation aims firstly to compare the efficacy of "Robin" in 30 CHR adolescents aged 14-18 to an active control group (treatment as usual) from a previous study. Primary outcome measures will be at-risk symptomatology, comorbid diagnosis, functioning, self-efficacy and quality of life. For the prospective intervention condition (16 weekly individual sessions + a minimum 4 family sessions), help-seeking adolescents with CHR for psychosis, aged 14-18, will be recruited over three years. At-risk and comorbid symptoms, functioning, self-efficacy and quality of life are monitored at six time points (baseline, during the treatment period, immediately after intervention, and 6, 12, and 24 months later) and compared to the respective measures of the active control group.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03829527
Study type Interventional
Source University of Zurich
Contact
Status Recruiting
Phase N/A
Start date September 1, 2017
Completion date September 30, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05827900 - Metacognitive Training in Ultra-high Risk N/A
Recruiting NCT02951208 - tDCS Coupled With Virtual Rehabilitation for Negative Symptoms in At-Risk Youth N/A
Completed NCT03983421 - Feasibility of an Early Detection Program for Early Psychosis on a College Campus
Recruiting NCT06037993 - Endocannabinoid Activity Remodulation for Psychosis Liability in Youth N/A
Completed NCT02404194 - Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis N/A
Completed NCT04444180 - The Predictive Role of Self-representation in Transition of Individuals at Clinical High Risk for Psychosis
Terminated NCT02047539 - Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis Early Phase 1
Recruiting NCT05114733 - Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST) N/A
Completed NCT03303456 - Using Mobile Technology to Enhance Early Psychosis Treatment Delivery N/A
Completed NCT03286595 - Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings N/A
Terminated NCT02557945 - Gabapentin in Patients at Clinical Risk for Psychosis Phase 1/Phase 2
Completed NCT03321617 - Glutamate Reducing Interventions in Schizophrenia Phase 1